This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Zafgen Cancels Meetings, Investors Fear the Worst

The heady days when a biotech company cancelling investor meetings was interpreted as a good thing -- perhaps a sign of a pending takeover -- appear to be over.

Lilly Sinks as Cholesterol-Lowering Pill Trial Shut Down

Eli Lilly is shutting down clinical development of a cholesterol-lowering pill, removing what could have been the company's next multi-billion-dollar product from its research pipeline.

Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments

Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.

Biogen Caused Biotech Collapse but Might Also Lead Stocks Higher

Biogen has the opportunity to make amends for its second-quarter earnings blow-up when it reports third-quarter earnings in two weeks.

Advaxis Cancer Immunotherapy on Hold Due to Patient Death

The FDA placed a halt on clinical trials involving a cancer immunotherapy from Advaxis because of concerns a bacteria used to deliver the drug contributed to a patient death.

Exact Sciences Tumbles on Colon Cancer Screening Snub

An independent panel of health care experts did not include Exact Sciences' Cologuard on a draft list of recommended colon cancer screening tests in the U.S.

MannKind Silent on Debt Conversion, Suggesting Costly Cash Settlement

Using cash to settle the debt was MannKind's worst-case option because it leaves the company with little money to fund ongoing operations.

Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters

There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.

Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Sarepta Unveils New Data to Make Stronger Case for Duchenne Drug Approval

Sarepta hopes the new data will convince FDA to approve eteplirsen as a new treatment for Duchenne early next year.

Page 1 of 343
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs